Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia - PubMed (original) (raw)
Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia
Wendy A G Stams et al. Clin Cancer Res. 2005.
Abstract
Purpose: t(12;21)(p13; q22), present in approximately 25% of pediatric precursor B-ALL, is highly sensitivity to L-asparaginase and the prognosis depends on the intensity of the treatment protocol. This study analyzes the relationship between the mRNA expression of the genes and fusion products involved in t(12;21), in vitro sensitivity to prednisolone, vincristine, and L-asparaginase, and long-term clinical outcome in t(12;21)+ acute lymphoblastic leukemia (ALL) patients.
Experimental design: Long-term clinical outcome in 45 t(12;21)+ ALL patients was related to mRNA expression of TEL, AML1, TEL-AML1, and AML1-TEL, determined by real-time quantitative PCR, and the in vitro sensitivity to prednisolone, vincristine, and L-asparaginase, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays.
Results: A significant approximately 3.5-fold lower TEL expression in t(12;21)+ compared with t(12;21)- ALL samples (P = 0.006) and normal controls (P = 0.004) was found. Expression of AML1 did not differ between t(12;21)+ and t(12;21)- ALL. However, AML1 expression in the leukemic cells was 2-fold higher compared with normal controls (P = 0.02). The TEL-AML1 fusion product was expressed in all t(12;21)+ cases, whereas the reciprocal fusion product AML1-TEL was expressed in only 76%. High expression levels of TEL-AML1 [hazard ratio (HR), 1.3; 95% confidence interval (95% CI), 1.10-1.57; P = 0.003], AML1-TEL (HR, 4.9; 95% CI, 1.99-12.40; P = 0.001) and AML1 (HR, 1.1; 95% CI, 1.03-1.22; P = 0.006) were associated with a poor long-term clinical outcome within t(12;21)+ ALL. Cellular drug resistance towards prednisolone, vincristine, and L-asparaginase could not explain this predictive value. Multivariate analysis including age and WBC showed that only high AML1-TEL expression is an independent poor prognostic factor in t(12;21)+ childhood ALL.
Conclusion: High AML1-TEL expression is an independent poor prognostic factor in t(12;21)+ childhood ALL.
Similar articles
- Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes.
Bolufer P, Barragán E, Verdeguer A, Cervera J, Fernández JM, Moreno I, Lerma E, Esquembre C, Tasso M, Fuster V, Bermúdez M, Sanz MA. Bolufer P, et al. Haematologica. 2002 Jan;87(1):23-32. Haematologica. 2002. PMID: 11801462 - Fluorescence in situ hybridization study of TEL/AML1 fusion and other abnormalities involving TEL and AML1 genes. Correlation with cytogenetic findings and prognostic value in children with acute lymphocytic leukemia.
Martínez-Ramírez A, Urioste M, Contra T, Cantalejo A, Tavares A, Portero JA, López-Ibor B, Bernacer M, Soto C, Cigudosa JC, Benítez J. Martínez-Ramírez A, et al. Haematologica. 2001 Dec;86(12):1245-53. Haematologica. 2001. PMID: 11726315 - The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F, Pisegna S, Diverio D. Lo Coco F, et al. Haematologica. 1997 May-Jun;82(3):364-70. Haematologica. 1997. PMID: 9234595 Review. - [The role of TEL and AML1 genes in the pathogenesis of hematologic malignancies].
Zuna J. Zuna J. Cas Lek Cesk. 2001 Mar 15;140(5):131-7. Cas Lek Cesk. 2001. PMID: 11347199 Review. Czech.
Cited by
- Current Role of Genetics in Hematologic Malignancies.
Prakash G, Kaur A, Malhotra P, Khadwal A, Sharma P, Suri V, Varma N, Varma S. Prakash G, et al. Indian J Hematol Blood Transfus. 2016 Mar;32(1):18-31. doi: 10.1007/s12288-015-0584-4. Epub 2015 Sep 16. Indian J Hematol Blood Transfus. 2016. PMID: 26855503 Free PMC article. Review. - Certainty in uncertainty: Determining the rate and reasons for reclassification of variants of uncertain significance in haematological malignancies.
Enjeti AK, Walker N, Fahey O, Johnston E, Legge-Wilkinson H, Ramsurrun N, Sillar J, Lincz LF, Ziolkowski A, Mossman D. Enjeti AK, et al. EJHaem. 2024 Sep 12;5(5):957-963. doi: 10.1002/jha2.1002. eCollection 2024 Oct. EJHaem. 2024. PMID: 39415915 Free PMC article. - The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing.
Lindqvist CM, Nordlund J, Ekman D, Johansson A, Moghadam BT, Raine A, Övernäs E, Dahlberg J, Wahlberg P, Henriksson N, Abrahamsson J, Frost BM, Grandér D, Heyman M, Larsson R, Palle J, Söderhäll S, Forestier E, Lönnerholm G, Syvänen AC, Berglund EC. Lindqvist CM, et al. Hum Mutat. 2015 Jan;36(1):118-28. doi: 10.1002/humu.22719. Hum Mutat. 2015. PMID: 25355294 Free PMC article. - Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms resulting in suboptimal oocyte maturation: a discussion of folate status, neural tube defects, schizophrenia, and vasculopathy.
Jongbloet PH, Verbeek AL, den Heijer M, Roeleveld N. Jongbloet PH, et al. J Exp Clin Assist Reprod. 2008 Jul 10;5:5. doi: 10.1186/1743-1050-5-5. J Exp Clin Assist Reprod. 2008. PMID: 18616826 Free PMC article. - Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.
Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, Lo MC, Yan M, Zhang DE. Peterson LF, et al. Blood. 2007 Aug 1;110(3):799-805. doi: 10.1182/blood-2006-11-019265. Epub 2007 Apr 5. Blood. 2007. PMID: 17412887 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources